X MAN Catalogue Q1, 2011

www.horizondiscovery.com

mutant and normal

isogenic human cell lines

TM X-MAN CatalogueIssue: Q1, 2011

Cell Lines

www.horizondiscovery.com 5

Cell Line Gene Genotype

Genes tagged at endogenous locus

HCT116 APC SBP-3xFlagHCT116 Asf1 CBP-3xFlagHCT116 Baz2a CBP-3xFlagHCT116 Bmi1 CBP-3xFlagRKO B-RAF mutant allele tagged with SBP-FlagRKO B-RAF wild type allele tagged with SBP-FlagDLD-1 CHD2 SBP-3xFlagDLD-1 CHD7 CBP-3xFlagDLD-1 CHD8 SBP-3xFlagRKO DNMT1 CBP-3xFlagDLD-1 DNMT3b CBP-3xFlagHCT116 Dot1l CBP-3xFlagHCT116 E2f1 CBP-3xFlagHCT116 Eed CBP-3xFlagHCT116 EzH2 CBP-3xFlagHCT116 IDH1 SBP-3xFlagHCT116 Kaiso SBP-3xFlagRKO Mre11 CBP-3xFlagLoVo Mre11 CBP-3xFlagHCT116 Mrgbp CBP-3xFlagDLD-1 PTPN14 CBP-3xFlagHCT116 Rcor2 CBP-3xFlagHCT116 Sirt6 CBP-3xFlagDLD-1 STAT3 CBP-3xFlagHCT116 Trim37 CBP-3xFlagHCT116 UHRF1 SBP-3xFlagHCT116 Zcchc4 CBP-3xFlag

Note: CBP-3xFlag calmodulin binding peptide (CBP)-3xFlag SBP-3xFlag streptavidin binding protein (SBP)-3xFlag

Additional Cell Lines

DLD-1 HAUSP/USP7 knock-out HCT116 Kaiso knock-out HCT116 BCAR1/p130CAS (Y128F) RKO BCAR1/p130CAS (Y128F)DLD-1 STAT3 knock-out HCT116 STAT3 (Y705F) RKO STAT3 (Y705F) DLD-1 STAT3 (Y705F) DLD-1 Paxillin (Y88F) HCT116 Paxillin (Y88F)

Cell Line Gene Genotype

New Cell Lines

www.horizondiscovery.com13


Single mutated cancer gene panel

HD100-001 HME EGFR (del E746-A750) Heterozygous activating kinase domain mutationHD100-002 HME PI3K! (H1047R) Heterozygous activating kinase domain mutationHD100-003 HME PI3K! (E545K) Heterozygous activating kinase domain mutationHD100-004 HME K-Ras (G13D) Heterozygous GTPase mutant leading to constitutive Ras-signallingHD100-005 HME B-Raf (V600E) Heterozygous activating kinase domain mutation

HD101-002 MCF10A PI3K! (E545K) Heterozygous activating hinge domain mutationHD101-004 MCF10A K-Ras (G12V) Heterozygous GTPase mutant leading to constitutive Ras-signallingHD101-005 MCF10A p53 null Homozygous tumour suppressor knock-out of exon 2HD101-006 MCF10A PTEN null Homozygous tumour suppressor knock-out of exon 2HD101-007 MCF10A AKT1 (E17K) Heterozygous activating PH domain mutationHD101-008 MCF10A B-Raf (V600E) Heterozygous knock-in of activating mutation; Neo resistantHD101-009 MCF10A "-Catenin (T41A) Heterozygous knock-in of activating mutation; Neo resistantHD101-010 MCF10A EGFR (del E746-A750) Heterozygous activating kinase domain mutationHD101-011 MCF10A PI3K! (H1047R) Heterozygous activating kinase domain mutationHD101-012 MCF10A B-Raf (V600E) Heterozygous knock-in of activating mutation; Neo sensitiveHD101-013 MCF10A IDH1 (R132H) Heterozygous knock-in of activating mutation; Neo resistant HD102-001 RPE-1 PI3K! (H1047R) Heterozygous activating kinase domain mutationHD102-002 RPE-1 PI3K! (E545K) Heterozygous activating hinge domain mutationHD102-003 RPE-1 EGFR (del E746-A750) Heterozygous activating kinase domain mutation HD103-001 SW48 PI3K! (E545K) Heterozygous activating hinge domain mutationHD103-002 SW48 K-Ras (G13D) Heterozygous GTPase mutant leading to constitutive Ras-signallingHD103-003 SW48 B-Raf (V600E) Heterozygous activating kinase domain mutationHD103-004 SW48 p53 null Homozygous tumour suppressor knock-outHD103-005 SW48 PI3K! (H1047R) Heterozygous knock-in of activating mutationHD103-006 SW48 K-Ras (G12C) Heterozygous GTPase mutant leading to constitutive Ras-signallingHD103-007 SW48 K-Ras (G12V) Heterozygous GTPase mutant leading to constitutive Ras-signallingHD103-008 SW48 p53 (R273H) Heterozygous knock-in of dominant negative mutation (R273H)HD103-009 SW48 K-Ras (G12A) Heterozygous GTPase mutant leading to constitutive Ras-signallingHD103-010 SW48 K-Ras (G12R) Heterozygous GTPase mutant leading to constitutive Ras-signallingHD103-011 SW48 K-Ras (G12D) Heterozygous GTPase mutant leading to constitutive Ras-signallingHD103-012 SW48 PTEN null Homozygous tumour suppressor knock-outHD103-013 SW48 K-Ras (G12S) Heterozygous GTPase mutant leading to constitutive Ras-signalling HD104-001 HCT116 p53 null Homozygous tumour suppressor knock-outHD104-002 HCT116 p53 (R248W) Heterozygous knock-in of mutant tumour supressorHD104-003 HCT116 p53 (R248W/-) Knock-in of mutant tumour supressor and knock-out of wild type alleleHD104-004 HCT116 PTEN null Homozygous tumour suppressor knock-out HD104-005 HCT116 SMAD4 null Homozygous tumour suppressor knock-outHD104-006 HCT116 MLH1 (wild type knock-in) Heterozygous knock-in of wild-type gene in mutant parent cellsHD104-007 HCT116 PI3K! (H1047R knock-out) Knock-out of mutant allele (H1047R) in heterozygous parental cellsHD104-008 HCT116 K-Ras (G13D knock-out) Knock-out of mutant allele (G13D) in heterozygous parental cells; GFP version availableHD104-009 HCT116 "-Catenin ( 45 knock-out) Knock-out of mutant allele ( 45) in heterozygous parental cellsHD104-010 HCT116 "-Catenin (wild type knock-out) Knock-out of wild type allele in heterozygous parental cellsHD104-011 HCT116 K-Ras (wild type knock-out) Knock-out of wild type allele in heterozygous parental cellsHD104-012 HCT116 PI3K! (wild type knock-out) Knock-out of wild type allele in heterozygous parental cellsHD104-013 HCT116 IDH1 (R132H) Heterozygous knock-in of activating mutation; Neo resistant

Catalogue No. Cell line Genotype Main Characteristics

new

new

new

new

new

new

new

All cell lines available OTS on simple licensing or collaborative terms. Custom cell line development and compound screening services also available.

new

new

new


Single mutated cancer gene panel

HD105-001 DLD-1 PI3K! (E545K knock-out) Knock-out of mutant allele in heterozygous parental cellsHD105-002 DLD-1 K-Ras (G13D knock-out) Knock-out of mutant allele in heterozygous parental cells; YFP version availableHD105-003 DLD-1 p53 (S241F/silenced) Parental DLD-1 is mutant/silencedHD105-004 DLD-1 p53 (-/silenced) Knock-out of mutant allele (S241F) (2nd Allele still silenced)HD105-005 DLD-1 p53 (wild type/silenced) Knock-in of wild type p53 into mutant allele (2nd Allele still silenced)HD105-007 DLD-1 BRCA2 null (del. exon 11/del. exon 11) Knock-out of DNA repair 'caretaker' gene (bi-allelic null)HD105-008 DLD-1 BRCA2 null (del. exon 11/Y3308X) Knock-out of DNA repair 'caretaker' gene (null/knock-in of inactivating point mutant )HD105-009 DLD-1 BRCA2 null (del. exon 11/S3291E) Knock-out of DNA repair 'caretaker' gene (null/knock-in hypomorphic point mutation)HD105-010 DLD-1 ATR (A2101G) Homozygous hypomorphic ATR mutation (Seckel); p53 mutant backgroundHD105-011 DLD-1 K-Ras (wild type knock-out) Knock-out of wild type allele in heterozygous parental cellsHD105-012 DLD-1 PI3K! (wild type knock-out) Knock-out of wild type allele in heterozygous parental cellsHD105-013 DLD-1 p53 (S241F/-) Knock-out of silenced p53 allele; Neo resistant. Replaces HD105-006 HD106-001 RKO p53 (R248W) Knock-in of mutant tumour supressorHD106-002 RKO p53 null Tumour suppressor knock-outHD106-003 RKO B-Raf (V600E knock-out) Knock-out of mutant allele in triploid parental cells (+/-/-)HD106-004 RKO B-Raf (wild type knock-out) Wild type allele knock-out in triploid parental cells (V600E/-/-)

HD 107-001 VACO 432 B-Raf (V600E knock-out) Knock-out of mutant allele in heterozygous parental cellsHD 107-002 VACO 432 B-Raf (wild type knock-out) Knock-out of wild type allele in heterozygous parental cells HD108-001 KMS11 MMSET (NTKO) Knock-out of non-translocated MMSET allele in a heterozygous Multiple Myeloma lineHD108-002 KMS11 MMSET (TKO) Knock-out of translocated MMSET allele in a heterozygous Multiple Myeloma line HD109-001 Panc 04.03 MKK4 null Knock-out of MMK4 (MAP2K4) in Pancreatic cell line



new


HD 200-001 HME PI3K! (H1047R) & EGFR (del E746-A750) Double knock-in of two cancer genesHD 200-002 HME EGFR (del E746-A750) & B-Raf (V600E) Double knock-in of two cancer genesHD 200-003 HME K-Ras (G13D) & PI3K! (H1047R) Double knock-in of two cancer genes HD 201-001 MCF10A PI3K! (H1047R) & EGFR (del E746-A750) Double knock-in of two cancer genesHD 201-002 MCF10A PI3K! (E545K) & K-Ras (G12V) Double knock-in of two cancer genesHD 201-003 MCF10A PI3K! (H1047R) & K-Ras (G12V) Double knock-in of two cancer genes HD 202-001 DLD-1 ATR (A2101G) & wild type p53 Homozygous hypomorphic ATR mutation (Seckel) and heterozygous knock-in of wild type p53 (wild type/silenced)


Double mutated cancer gene panel


HD R00-001 DLD-1 AKT1 (-/- )HD R00-002 DLD-1 AKT2 (-/-)HD R00-003 DLD-1 AKT1 (-/-) & AKT2 (-/-)HD R00-004 DLD-1 B-Raf (-/-)HD R00-005 DLD-1 CDC4 (-/-)HD R00-006 DLD-1 CDC4 (+/-)HD R00-007 DLD-1 CHK1 knock-out (S317A heterozygous knock-in)HD R00-008 DLD-1 CHK1 knock-out (S317A/S317A double knock-in)HD R00-009 DLD-1 Dicer (-/-)HD R00-010 DLD-1 Inducible mutant p53HD R00-011 DLD-1 Inducible mutant p73HD R00-012 DLD-1 Inducible wild type p53HD R00-013 DLD-1 Inducible wild type p73HD R00-014 DLD-1 Inducible PUMAHD R00-015 DLD-1 Inducible GFPHD R00-016 DLD-1 Inducible TbRIIHD R00-017 DLD-1 MEK1 (-/-)HD R00-018 DLD-1 MEK2 (-/-)HD R00-019 DLD-1 MEK2 (+/-)HD R00-020 DLD-1 p21 (-/-)HD R00-021 DLD-1 MTAP (-/-)HD R00-022 DLD-1 TCF4 Inducible LuciferaseHD R00-023 DLD-1 XIAP (-/-)HD R00-024 DLD-1 GLUT1 (-/-)HD R00-025 DLD-1 ATR (A2101G/+) & p53 wild type knock-in (wild type/silenced)HD R00-026 DLD-1 CHK1 heterozygous (+/-) & p53 wild type knock-in (wild type/silenced)HD R00-027 DLD-1 CHK1 heterozygous (+/-) in p53 mutant background

HD R01-001 HACAT DEC1 (-/-)HD R01-002 HACAT DEC1 (+/-) HD R02-001 HCT116 14-3-3 sigma (-/-)HD R02-002 HCT116 14-3-3 sigma (+/-)HD R02-003 HCT116 14-3-3 sigma (-/-) & p21 (-/-)HD R02-004 HCT116 AKT1 (-/-)HD R02-005 HCT116 AKT2 (-/-)HD R02-006 HCT116 AKT1 (-/-) & AKT2 (-/-)HD R02-007 HCT116 APOC1 (-/-)HD R02-008 HCT116 BAX (-/-)HD R02-009 HCT116 BAX (+/-)HD R02-010 HCT116 BAX (-/-) & p21 (-/-)HD R02-011 HCT116 BLM (-/-)HD R02-012 HCT116 B-Raf (-/-)HD R02-013 HCT116 CDC4 (-/-)HD R02-014 HCT116 CDC4 (+/-)HD R02-015 HCT116 CDK2 (-/-)HD R02-016 HCT116 CDK2 (-/-) & p53 knock-out (-/-)HD R02-017 HCT116 CHK2 (-/-)HD R02-018 HCT116 CHK2 (-/-) & p53 knock-out (-/-)HD R02-019 HCT116 Dicer (-/-)HD R02-020 HCT116 DNMT1 (-/-)HD R02-021 HCT116 DNMT1 (+/-)HD R02-022 HCT116 DNMT1 (-/-) & DNMT3b (-/-) (DKO)HD R02-023 HCT116 DNMT3b (-/-)


Catalogue No. Cell line Genotype (Knock Outs, unless otherwise stated)

Cancer associated/modifier gene panelResearcher


new

new

new



HD R02-024 HCT116 DNMT1 (-/-) & DNMT3b (-/-) & p16 (mutant/-) (TKO)HD R02-025 HCT116 DNMT1 (-/-) & DNMT3b (-/-) & p16 (-/wild type) (TKO)HD R02-026 HCT116 DNMT1 (+/-) & DNMT3b (-/-) & p16 (mutant/-) (TKO)HD R02-027 HCT116 DNMT1(+/-) & DNMT3a (+/-) & DNMT3b (-/-) & p16 (mutant/-) (TKO)HD R02-028 HCT116 HAUSP (-/-)HD R02-029 HCT116 HAUSP (+/-)HD R02-030 HCT116 MEK1 (-/-)HD R02-031 HCT116 MEK2 (-/-)HD R02-032 HCT116 MEK2 (+/-)HD R02-033 HCT116 MTAP (-/-)HD R02-034 HCT116 p16 (wild type allele knock-out)HD R02-035 HCT116 p21 (-/-)HD R02-036 HCT116 p21(+/-)HD R02-037 HCT116 p53 (+/-)HD R02-038 HCT116 PPAR delta (-/-)HD R02-039 HCT116 PPAR delta (+/-)HD R02-040 HCT116 PUMA (-/-)HD R02-041 HCT116 PUMA (-/-) & p21 (-/-)HD R02-042 HCT116 K-Ras (wild type allele knock-out; GFP/YFP versions available)HD R02-043 HCT116 Securin (-/-)HD R02-044 HCT116 Securin (+/-)HD R02-045 HCT116 Smac/Diablo (-/-)HD R02-046 HCT116 SMAD4 (+/-)HD R02-047 HCT116 XIAP (-/-)HD R02-048 HCT116 DNA-PKcs (+/-)HD R02-049 HCT116 DNA-PKcs (-/-)HD R02-050 HCT116 DNA-PKcs (-/-) & DNA-PKcs cDNA over-expressionHD R02-051 HCT116 DNA-PKcs (-/-) & Ku70 (+/NEO)HD R02-052 HCT116 HPRT (-/0)HD R02-053 HCT116 Ku70 (+/-)HD R02-054 HCT116 Ku86 (+/flox)HD R02-055 HCT116 Ku86 (-/flox)HD R02-056 HCT116 Ku86 (-/flox) & LIGIV (+/-)HD R02-057 HCT116 Ku86 (-/flox) & LIGIV (-/-)HD R02-058 HCT116 Ku86 (-/flox) & RAD54B (+/+/-)HD R02-059 HCT116 Ku86 (-/flox) & RAD54B (+/-/-)HD R02-060 HCT116 LIGIII (+/flox)HD R02-061 HCT116 LIGIII (-/flox)HD R02-062 HCT116 LIGIV (+/-)HD R02-063 HCT116 LIGIV (-/-)HD R02-064 HCT116 LIGIV (-/-) & Ku70 (+/NEO)HD R02-065 HCT116 LIGIV (-/-) & RAD54B (+/+/-)HD R02-066 HCT116 LIGIV (-/-) & RAD54B (+/-/-)HD R02-067 HCT116 XLF (+/-)HD R02-068 HCT116 XLF (-/-)HD R02-069 HCT116 XLF (-/-) & XLF cDNA over-expressionHD R02-070 HCT116 XLF (-/-) & XLF cDNA over-expression (L115A)HD R02-071 HCT116 XLF (-/-) & XLF cDNA over-expression (L179A)HD R02-072 HCT116 XLF (-/-) & XLF cDNA over-expression (R57G)HD R02-073 HCT116 XLF (-/-) & XLF cDNA over-expression (C123R)HD R02-074 HCT116 XLF (-/-) & XLF cDNA over-expression (R178X)HD R02-075 HCT116 XRCC4 (+/-)HD R02-076 HCT116 XRCC4 (-/-)HD R02-077 HCT116 Chk1 heterozygous (+/-) in p53 wild type backgroundHD R02-078 HCT116 Chk1 heterozygous (+/-) in p53 null backgroundHD R02-079 HCT116 DNMT1 (-/-) & DNMT3B (-/-) (retains methylation)




new

new

new


HD R03-001 HT-29 Inducible APCHD R03-002 HT-29 Inducible beta-galactosidase HD R05-001 RKO Dicer (-/-)HD R05-002 RKO FANCG (+/-)HD R05-003 RKO FANCC (+/+/-)HD R05-004 RKO FANCC (+/-/-)HD R05-005 RKO FANCG (-/-)HD R05-006 RKO FANCC (-/-/-)HD R05-007 RKO MEK2 (-/-)HD R05-008 RKO MEK2 (+/-)HD R05-009 RKO p53 (+/-)HD R05-010 RKO MEK1 (-/-)HD R05-011 RKO GLUT1 (-/-)HD R05-012 RKO B-Raf (V600E/+/-) HD R06-001 SW48 p53 (+/-) HD R07-001 VACO 432 MEK1 (-/-) HD R07-002 VACO 432 MEK2 (-/-)HD R07-003 VACO 432 MEK2 (+/-) HD R08-001 NALM-6 DNA-PKcs (+/-)HD R08-002 NALM-6 Ku70 (+/-)HD R08-003 NALM-6 Ku86 (+/-) HD R09-001 BJ DNA-PKcs (+/-) HD R10-001 RPE Artemis (+/-)HD R10-002 RPE CCR5 (+/-)HD R10-003 RPE DNA-PKcs (+/-)HD R10-004 RPE XRCC4 (+/-) HD R11-001 MCF10A PTEN (+/-)





new

new



HD101-005 MCF10A p53 nullHD103-004 SW48 p53 nullHD103-008 SW48 p53 (R273H)HD104-001 HCT116 p53 null HD104-002 HCT116 p53 (R248W) HD104-003 HCT116 p53 (R248W/-)HD R02-037 HCT116 p53 (+/-)HD105-003 DLD-1 p53 (S241F/silenced) HD105-004 DLD-1 p53 (-/silenced) HD105-005 DLD-1 p53 (wild type/silenced) HD105-013 DLD-1 p53 (S241F/-)HD106-001 RKO p53 (R248W)HD106-002 RKO p53 null

HD105-007 DLD-1 BRCA2 null (del. exon 11/del. exon 11) HD105-008 DLD-1 BRCA2 null (del. exon 11/Y3308X) HD105-009 DLD-1 BRCA2 null (del. exon 11/S3291E)

HD105-010 DLD-1 ATR (A2101G)HD 202-001 DLD-1 ATR (A2101G) & wild type p53HD R00-025 DLD-1 ATR (A2101G/+) & p53 wild type knock-in (wild type/silenced)

HD R00-007 DLD-1 CHK1 knock-out (S317A heterozygous knock-in)HD R00-008 DLD-1 CHK1 knock-out (S317A/S317A double knock-in) HD R00-026 DLD-1 CHK1 heterozygous (+/-) & p53 wild type knock-in (wild type/silenced)HD R00-027 DLD-1 CHK1 heterozygous (+/-) in p53 mutant backgroundHD R02-077 HCT116 CHK1 heterozygous (+/-) in p53 wild type backgroundHD R02-078 HCT116 CHK1 heterozygous (+/-) in p53 null background HD R02-017 HCT116 CHK2 (-/-)HD R02-018 HCT116 CHK2 (-/-) & p53 knock-out (-/-)


Catalogue No. Cell line Genotype

DNA repair enzyme/modifier gene panelDNArepair



HD R02-011 HCT116 BLM (-/-)HD104-006 HCT116 MLH1 (wild type knock-in)HD R02-048 HCT116 DNA-PKcs (+/-)HD R02-049 HCT116 DNA-PKcs (-/-)HD R02-050 HCT116 DNA-PKcs (-/-) & DNA-PKcs cDNA over-expressionHD R02-051 HCT116 DNA-PKcs (-/-) & Ku70 (+/NEO)HD R02-053 HCT116 Ku70 (+/-)HD R02-054 HCT116 Ku86 (+/flox)HD R02-055 HCT116 Ku86 (-/flox)HD R02-056 HCT116 Ku86 (-/flox) & LIGIV (+/-)HD R02-057 HCT116 Ku86 (-/flox) & LIGIV (-/-)HD R02-058 HCT116 Ku86 (-/flox) & RAD54B (+/+/-)HD R02-059 HCT116 Ku86 (-/flox) & RAD54B (+/-/-)HD R02-060 HCT116 LIGIII (+/flox)HD R02-061 HCT116 LIGIII (-/flox)HD R02-062 HCT116 LIGIV (+/-)HD R02-063 HCT116 LIGIV (-/-)HD R02-064 HCT116 LIGIV (-/-) & Ku70 (+/NEO)HD R02-065 HCT116 LIGIV (-/-) & RAD54B (+/+/-)HD R02-066 HCT116 LIGIV (-/-) & RAD54B (+/-/-)HD R02-067 HCT116 XLF (+/-)HD R02-068 HCT116 XLF (-/-)HD R02-069 HCT116 XLF (-/-) & XLF cDNA over-expressionHD R02-070 HCT116 XLF (-/-) & XLF cDNA over-expression (L115A)HD R02-071 HCT116 XLF (-/-) & XLF cDNA over-expression (L179A)HD R02-072 HCT116 XLF (-/-) & XLF cDNA over-expression (R57G)HD R02-073 HCT116 XLF (-/-) & XLF cDNA over-expression (C123R)HD R02-074 HCT116 XLF (-/-) & XLF cDNA over-expression (R178X)HD R02-075 HCT116 XRCC4 (+/-)HD R02-076 HCT116 XRCC4 (-/-)


Catalogue No. Cell line Genotype

DNA repair enzyme/modifier gene panelDNArepair


In Development

Cell line Genotype Main Characteristics

www.horizondiscovery.com12 www.horizondiscovery.com21

For more information please contact:

Horizon Discovery Ltd.

Building 7300 IQ Cambridge Waterbeach Cambridge CB25 9TL United Kingdom

Tel: +44 (0)1223 655583 - Fax: +44 (0)1223 862240 - E mail: [email protected]

© 2010, Horizon Discovery Ltd. X-MAN and X-MAN logo are registered trade marks of Horizon Discovery Ltd.

300+ ready to ship isogenic cell lines including p53, K-Ras, B-Raf, PI3K! and EGFR

Custom cell lines with your endogenous DNA sequence of interest; SNPs, knock-ins and knock-outs

Compound screening, standard and bespoke assay development (in vitro and in vivo)

Genomic standards and reference materials for companion diagnostics

If you require any further information or wish to discuss your requirements, please call us on +44 (0) 1223 655583 (UK) or +1 617 4184190 (USA) or e-mail [email protected]

X MAN Catalogue Q1, 2011

Documents

Transcript of X MAN Catalogue Q1, 2011